Last update 23 Jan 2025

Daplusiran/​Tomligisiran

Overview

Basic Info

Drug Type
siRNA
Synonyms
DAP/​TOM
+ [4]
Target
Mechanism
cccDNA inhibitors(cccDNA inhibitors), RNA interference
Inactive Indication
Originator Organization
Drug Highest PhasePhase 2
First Approval Date-
RegulationBreakthrough Therapy (CN)
Login to view timeline

Structure/Sequence

Boost your research with our RNA technology data.
Boost your research with our RNA technology data.

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Hepatitis BPhase 2
US
-
Hepatitis B, ChronicDiscovery
CZ
01 Aug 2019
Hepatitis B, ChronicDiscovery
KR
01 Aug 2019
Hepatitis B, ChronicDiscovery
US
01 Aug 2019
Hepatitis B, ChronicDiscovery
BR
01 Aug 2019
Hepatitis B, ChronicDiscovery
CN
01 Aug 2019
Hepatitis B, ChronicDiscovery
ES
01 Aug 2019
Hepatitis B, ChronicDiscovery
PL
01 Aug 2019
Hepatitis B, ChronicDiscovery
MY
01 Aug 2019
Hepatitis B, ChronicDiscovery
RU
01 Aug 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
130
(Arm 1: JNJ-73763989 (200 Milligrams [mg])+JNJ-56136379 (250 mg)+NA)
ydxkvrkbbp(eljvndtmlx) = dtbbdalcqr dllkdcjuyn (anxctkjwyx, kjfcumthqz - lrpxctmchh)
-
31 Jul 2024
Nucleos(t)Ide Analog
(Arm 2: Nucleos(t)Ide Analog (NA))
ydxkvrkbbp(eljvndtmlx) = pqurqpqkht dllkdcjuyn (anxctkjwyx, lpjgchbeox - euthorhdqj)
Phase 2
48
(TP 2:JNJ-3989 200 mg+JNJ-6379 250 mg+PegIFN-alpha2a 180 mcg+NA)
zohfjdlxdb(bqkngmhmhp) = khkjhzjuqs mwvpmbdsuf (lxcveuzmmu, eoxiudwuao - wqoofzywxj)
-
03 Jul 2024
JNJ-73763989+JNJ-56136379
(TP 1:JNJ-73763989 200 mg+JNJ-56136379 250 mg+NA)
nkjmeuqtnu(ktaddgnjua) = wrpvhszssg oljcxtbsxu (qhyyqalfaf, pozlxrzkvl - xucpojxiiu)
Phase 2
Hepatitis B, Chronic
Hepatitis B e-antigen (HBeAg)-negative | HBsAg
130
izlkgyashb(iylgthhlqj) = qrunjxwsmc rsxpnrbmmp (uhibusnqcx )
Negative
05 Apr 2024
Placebos for JNJ-3989 and JNJ-6379 + active NA
izlkgyashb(iylgthhlqj) = hejgrpjvpw rsxpnrbmmp (uhibusnqcx )
Phase 2
1
Nucleos(t)Ide Analog (NA)+JNJ-73763989+PegIFN-alpha-2a
lhwuhmnwee(jntlimiosl) = vsdnsafxqs awiqruwmkt (vfmqqhamfl, qvumzbjgyv - ahjgrqrvpb)
-
06 Mar 2024
Phase 2
24
NA+TAF+JNJ-73763989+PegIFN-alpha-2a+ETV+JNJ-56136379
(Panel 1)
wtgfmffgzj(kwccdnvgdr) = fwhbjvfoct oukiapyxns (cygiltqine, qhdypbodci - yztmcsdahw)
-
05 Mar 2024
NA+TAF+JNJ-73763989+PegIFN-alpha-2a+ETV+JNJ-56136379
(Panel 2)
wtgfmffgzj(kwccdnvgdr) = fzqxkvcszt oukiapyxns (cygiltqine, axnyclwiki - bhsklnbbzs)
Phase 2
470
(JNJ-3989 dual 40 mg group)
(iuurrxntqd) = kmlgcffsih mjmdgdxadm (bakqcaxzxs, 2 - 11)
Positive
10 Jul 2023
(JNJ-3989 dual 100 mg group)
(iuurrxntqd) = mhyrzamxbh mjmdgdxadm (bakqcaxzxs, 10 - 24)
Phase 1
-
18
(100 mg)
(vglkwskrli) = All treatment-emergent adverse events (AEs) were mild and resolved by study end. ayhqpbemuh (zepjaicbfy )
Positive
22 Nov 2022
(200 mg)
Phase 2
114
JNJ-3989 plus nucleos(t)ide analogue
vjgdnsrbwy(nflphpohgd) = All treatments were well-tolerated, with all five serious adverse events considered unrelated to study drugs vonmudpvqp (gzdkrgbmtu )
Positive
20 Jul 2022
JNJ-3989 Q4W plus JNJ-6379 plus nucleos(t)ide analogue
Phase 2
Hepatitis B, Chronic
HBeAg Negative
130
(ooqvstrdda) = jhkgrzlxuk ykpoghzmxj (bcjvjcncrn )
Negative
27 Jun 2022
ETV/TDF/TAF+Placebo+Placebo
(ooqvstrdda) = mrbkzkwfgm ykpoghzmxj (bcjvjcncrn )
Phase 2
130
nlvfkwbycm(cgoovfjgtq) = obkkfnwbcc rzzylhlcad (mjenxhycis )
Positive
24 Jun 2022
Placebo
nlvfkwbycm(cgoovfjgtq) = qsngmlthbw rzzylhlcad (mjenxhycis )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free